<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="8887">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02991261</url>
  </required_header>
  <id_info>
    <org_study_id>CLR_16_29</org_study_id>
    <nct_id>NCT02991261</nct_id>
  </id_info>
  <brief_title>Bioavailability Study of SPARC001 (Study 2) in Healthy Adult Volunteers</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Pharma Advanced Research Company Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Pharma Advanced Research Company Limited</source>
  <brief_summary>
    <textblock>
      The objective of the study is to determine the relative bioavailability, safety and
      tolerability of SPARC001 and Reference001 in healthy, adult, male and female subjects
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>February 2017</start_date>
  <completion_date type="Anticipated">April 2017</completion_date>
  <primary_completion_date type="Anticipated">April 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUC</measure>
    <time_frame>48 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>48 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse event</measure>
    <time_frame>25 days</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>SPARC001 type I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment type I</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SPARC001 type II</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment type II</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Reference001 type I</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Hydrocodone-Acetaminophen</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Reference type II</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Hydrocodone-Acetaminophen</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Treatment type I</intervention_name>
    <arm_group_label>SPARC001 type I</arm_group_label>
    <arm_group_label>SPARC001 type II</arm_group_label>
    <arm_group_label>Reference001 type I</arm_group_label>
    <arm_group_label>Reference type II</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Treatment type II</intervention_name>
    <arm_group_label>SPARC001 type I</arm_group_label>
    <arm_group_label>SPARC001 type II</arm_group_label>
    <arm_group_label>Reference001 type I</arm_group_label>
    <arm_group_label>Reference type II</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydrocodone Acetaminophen</intervention_name>
    <arm_group_label>SPARC001 type I</arm_group_label>
    <arm_group_label>SPARC001 type II</arm_group_label>
    <arm_group_label>Reference001 type I</arm_group_label>
    <arm_group_label>Reference type II</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Adult, male and female volunteers, 18 to 55 years of age, inclusive, at first
             Check-In Visit

          2. Body mass index (BMI) ≥18 to ≤30 kg/m2 and total body weight &gt;50 kg (110 lbs) at
             Screening

          3. All female subjects must have a negative serum pregnancy test at Screening and at
             each Check-in Visit

          4. Medically healthy on the basis of medical history and physical examination (including
             but not limited to an evaluation of the cardiovascular, gastrointestinal, respiratory
             and central nervous systems), as determined by the Investigator at Screening and each
             Check-In Visit.

        Exclusion Criteria:

          1. Females who are pregnant, lactating, or likely to become pregnant during the study

          2. Life-time history and/or recent evidence of alcohol or drug/substance abuse disorder

          3. Subjects who need to maintain mental alertness throughout the study

          4. Subjects determined by the investigator to have any medical condition that could
             jeopardize their health or prejudice the results
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Shravanti Bhowmik, MD</last_name>
    <phone>912266455645</phone>
    <email>shravanti.bhowmik@sparcmail.com</email>
  </overall_contact>
  <verification_date>December 2016</verification_date>
  <lastchanged_date>December 15, 2016</lastchanged_date>
  <firstreceived_date>December 8, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hydrocodone</mesh_term>
    <mesh_term>Acetaminophen, hydrocodone drug combination</mesh_term>
    <mesh_term>Oxycodone</mesh_term>
    <mesh_term>Acetaminophen</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
